It’s a similar situation for who will host or perform in the first few episodes; we probably won’t know until September. Sigh ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

The company will pay $140.6 million to settle claims that it illegally exported products to China. Separately, Cadence posted higher revenue in the second quarter and boosted its full-year earnings ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline ...